tiprankstipranks
ADC Therapeutics and the Perils of Outsourced Trials: Navigating the Uncertainty of ZYNLONTA’s Phase 2 Study
PremiumCompany AnnouncementsADC Therapeutics and the Perils of Outsourced Trials: Navigating the Uncertainty of ZYNLONTA’s Phase 2 Study
2M ago
ADC Therapeutics files $300M mixed securities shelf
Premium
The Fly
ADC Therapeutics files $300M mixed securities shelf
4M ago
ADC Therapeutics sees cash runway into mid-2026
Premium
The Fly
ADC Therapeutics sees cash runway into mid-2026
4M ago
ADC Therapeutics set to join Russell 2000, Russell 3000 Indexes
PremiumThe FlyADC Therapeutics set to join Russell 2000, Russell 3000 Indexes
5M ago
ADC Therapeutics participates in a conference call with JPMorgan
Premium
The Fly
ADC Therapeutics participates in a conference call with JPMorgan
5M ago
ADC Therapeutics rises 15.4%
Premium
The Fly
ADC Therapeutics rises 15.4%
6M ago
ADC Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
PremiumThe FlyADC Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
7M ago
ADC Therapeutics Ltd’s Business At Risk: The Perils of Limited Control in Clinical Trials
Premium
Company Announcements
ADC Therapeutics Ltd’s Business At Risk: The Perils of Limited Control in Clinical Trials
7M ago
ADC Therapeutics prices 13.4M shares at $4.90 in underwritten offering
Premium
The Fly
ADC Therapeutics prices 13.4M shares at $4.90 in underwritten offering
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100